Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 205

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Open access
Schmidt, Amand F, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, Juan P · 2017 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted, especially for people who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) reduce LDL-C and CVD risk. OBJECTIVES: Primary To quantify the effects of PCSK9 inhibitors on CVD, all-cause mortality, myocardial infarction, and stroke, compared to placebo or active treatment(s) for primary and secondary prevention. Secondary To quantify the safety of PCSK9 inhibitors, with specific focus on the incidence of influenza, hypertension, type 2 diabetes, and cancer, compared to placebo or active treatment(s) for primary and secondary prevention. SEARCH METHODS: We identified studies by systematically searching CENTRAL, MEDLINE, Embase, and Web of Science in December 2019. We also searched ClinicalTrials.gov and the International Clinical Trials Registry Platform in August 2020 and screened the reference lists of included studies. This is an update of the review first published in 2017. SELECTION CRITERIA: All parallel-group and factorial randomised controlled trials (RCTs) with a follow-up of at least 24 weeks were eligible. DATA COLLECTION AND ANALYSIS: Two review authors independently reviewed and extracted data. Where data were available, we calculated pooled effect estimates. We used GRADE to assess certainty of evidence and in 'Summary of findings' tables. MAIN RESULTS: We included 24 studies with data on 60,997 participants. Eighteen trials randomised participants to alirocumab and six to evolocumab. All participants received background lipid-lowering treatment or lifestyle counselling. Six alirocumab studies used an active treatment comparison group (the remaining used placebo), compared to three evolocumab active comparison trials. Alirocumab compared with placebo decreased the risk of CVD events, with an absolute risk difference (RD) of -2% (odds ratio (OR) 0.87, 95% confidence interval (CI) 0.80 to 0.94; 10 studies, 23,868 participants; high-certainty evidence), decreased the risk of mortality (RD -1%; OR 0.83, 95% CI 0.72 to 0.96; 12 studies, 24,797 participants; high-certainty evidence), and MI (RD -2%; OR 0.86, 95% CI 0.79 to 0.94; 9 studies, 23,352 participants; high-certainty evidence) and for any stroke (RD 0%; OR 0.73, 95% CI 0.58 to 0.91; 8 studies, 22,835 participants; high-certainty evidence). Compared to active treatment the alirocumab effects, for CVD, the RD was 1% (OR 1.37, 95% CI 0.65 to 2.87; 3 studies, 1379 participants; low-certainty evidence); for mortality, RD was -1% (OR 0.51, 95% CI 0.18 to 1.40; 5 studies, 1333 participants; low-certainty evidence); for MI, RD was 1% (OR 1.45, 95% CI 0.64 to 3.28, 5 studies, 1734 participants; low-certainty evidence); and for any stroke, RD was less than 1% (OR 0.85, 95% CI 0.13 to 5.61; 5 studies, 1734 participants; low-certainty evidence). Compared to placebo the evolocumab, for CVD, the RD was -2% (OR 0.84, 95% CI 0.78 to 0.91; 3 studies, 29,432 participants; high-certainty evidence); for mortality, RD was less than 1% (OR 1.04, 95% CI 0.91 to 1.19; 3 studies, 29,432 participants; high-certainty evidence); for MI, RD was -1% (OR 0.72, 95% CI 0.64 to 0.82; 3 studies, 29,432 participants; high-certainty evidence); and for any stroke RD was less than -1% (OR 0.79, 95% CI 0.65 to 0.94; 2 studies, 28,531 participants; high-certainty evidence). Compared to active treatment, the evolocumab effects, for any CVD event RD was less than -1% (OR 0.66, 95% CI 0.14 to 3.04; 1 study, 218 participants; very low-certainty evidence); for all-cause mortality, the RD was less than 1% (OR 0.43, 95% CI 0.14 to 1.30; 3 studies, 5223 participants; very low-certainty evidence); and for MI, RD was less than 1% (OR 0.66, 95% CI 0.23 to 1.85; 3 studies, 5003 participants; very low-certainty evidence). There were insufficient data on any stroke. AUTHORS' CONCLUSIONS: The evidence for the clinical endpoint effects of evolocumab and alirocumab were graded as high. There is a strong evidence base to prescribe PCSK9 monoclonal antibodies to people who might not be eligible for other lipid-lowering drugs, or to people who cannot meet their lipid goals on more traditional therapies, which was the main patient population of the available trials. The evidence base of PCSK9 inhibitors compared with active treatment is much weaker (low very- to low-certainty evidence) and it is unclear whether evolocumab or alirocumab might be effectively used as replacement therapies. Related, most of the available studies preferentially enrolled people with either established CVD or at a high risk already, and evidence in low- to medium-risk settings is minimal. Finally, there is very limited evi

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd011748.pub2

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 59

  1. Ballantyne, 2015, Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia, American Journal of Cardiology, 115, 1212, 10.1016/j.amjcard.2015.02.006 · DOI · Paper page
  2. Tingley W Mosesova S Baruch A Davis JD Budha N Vilimovskij A Effects of RG7652, a monoclonal antibody against proprotein convertase Subtilisin/Kexin type 9, on LDL cholesterol in patients with coronary heart disease or high risk: results from the EQUATOR study European Heart Journal 2014 371
  3. Stroes E Guyton JR Farnier M Rader D Moriarty PM Bergeron J Efficacy and safety of 150 mg and 300 mg every 3 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies Journal of the American College of Cardiology 2015 Exhibit 99.1
  4. Stroes E Guyton JR Farnier M Rader D Moriarty PM Bergeron J Efficacy and safety of 150 mg and 300 mg every 3 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies Journal of the American College of Cardiology 2015 Exhibit 99.1
  5. Cannon, 2015, Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial, European Heart Journal, 36, 1186, 10.1093/eurheartj/ehv028 · DOI · Paper page
  6. Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, European Heart Journal, 36, 2996
  7. Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, European Heart Journal, 36, 2996
  8. Ginsberg HN Rader DJ Raal F Guyton JR Lorenzato C Pordy R ODYSSEY HIGH FH: Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia Conference abstract Published online 2014
  9. Roth, 2014, Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial, International Journal of Cardiology, 176, 55, 10.1016/j.ijcard.2014.06.049 · DOI · Paper page
  10. Bays, 2015, Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial, Journal of Clinical Endocrinology and Metabolism, 100, 3140, 10.1210/jc.2015-1520 · DOI · Paper page
  11. Farnier, 2016, Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial, Atherosclerorsis, 244, 138, 10.1016/j.atherosclerosis.2015.11.010 · DOI · Paper page
  12. Koren, 2014, Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial, Circulation, 129, 234, 10.1161/CIRCULATIONAHA.113.007012 · DOI · Paper page
  13. Cho L Rocco M Colquhoun D Sullivan D Rosenson RS Dent R Clinical profile of statin intolerance in the phase 3 gauss-2 study Canadian Journal of Cardiology 2014 S79 · DOI
  14. Desai, 2014, AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of National Cholesterol Education Program-Adult Treatment Panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57), Journal of the American College of Cardiology, 63, 430, 10.1016/j.jacc.2013.09.048 · DOI
  15. Dias, 2012, Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins, Journal of the American College of Cardiology, 60, 1888, 10.1016/j.jacc.2012.08.986 · DOI · Paper page
  16. Gaudet, 2013, Alirocumab, a fully human monoclonal antibody to PCSK9, reduces high plasma lp(a) concentration: pooled analysis of 352 patients from phase 2, Journal of Clinical Lipidology, 7, 283, 10.1016/j.jacl.2013.03.091 · DOI
  17. Jones PH Bays H Chaudhari U Pordy R Lorenzato C Miller K Pooled safety and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical trials of alirocumab Journal of the American College of Cardiology 2015 A1363 · DOI
  18. Kastelein J Nissen S Rader D Krueger K Wang MD Safety and efficacy of LY 3015014, a new monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK 9) with an inherently longer duration of action, in patients with primary hypercholesterolemia: a randomized, placebo-controlled, dose-ranging, phase 2 study Journal of the American College of Cardiology 2015 A1591 · DOI
  19. Kawashiri, 2012, Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia, American Journal of Cardiology, 109, 364, 10.1016/j.amjcard.2011.09.019 · DOI
  20. Mabuchi, 2015, Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia, Nature Reviews Endocrinology, 11, 8, 10.1038/nrendo.2014.205 · DOI
  21. Maxwell, 2012, Antibodies to PCSK9: a superior way to lower LDL cholesterol?, Circulation Research, 111, 274, 10.1161/CIRCRESAHA.112.275859 · DOI
  22. Mearns, 2014, Dyslipidaemia: 1-year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab, Nature Reviews Cardiology, 11, 63, 10.1038/nrcardio.2013.201 · DOI
  23. Pordy, 2013, Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in phase 3 studies, Journal of Clinical Lipidology, 7, 279, 10.1016/j.jacl.2013.03.084 · DOI
  24. Raal F Nelson P Langslet G Basart DCG Civeira F Lopez-Miranda J Safety, tolerability, and efficacy of long-term administration of monthly AMG 145 in subjects with heterozygous familial hypercholesterolemia Global Heart 2014 e139 · DOI
  25. Shaywitz AJ Dias C Smith B Gao B Gibbs J Emery M AMG 145, a fully human monoclonal antibody against PCSK9, reduces LDL-C in healthy volunteers and patients on stable doses of statins+ Journal of Clinical Lipidology 2012 286 7 · DOI
  26. Stawowy, 2014, Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia, Coronary Artery Disease, 25, 353, 10.1097/MCA.0000000000000113 · DOI
  27. Swergold, 2010, Safety, lipid, and lipoprotein effects of REGN727/SAR236553, a fully-human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody administered intravenously to healthy volunteers, Circulation, 122, 2
  28. Wan H Gumbiner B Joh T Udata C Forgues P Garzone PD Effects of RN316 (pf-04950615), a humanized igg2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, on lipoprotein particles in hypercholesterolemic subjects Journal of the American College of Cardiology 2013 E1387 · DOI
  29. Abifadel, 2013, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nature Genetics, 34, 154, 10.1038/ng1161 · DOI · Paper page
  30. Altman, 2003, Interaction revisited: the difference between two estimates, BMJ, 326, 219, 10.1136/bmj.326.7382.219 · DOI · Paper page
  31. Benn, 2010, PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses, Journal of the American College of Cardiology, 55, 2833, 10.1016/j.jacc.2010.02.044 · DOI · Paper page
  32. Catapano, 2013, The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway, Atherosclerosis, 228, 18, 10.1016/j.atherosclerosis.2013.01.044 · DOI
  33. Chasman, 2012, Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, Circulation. Cardiovascular Genetics., 5, 257, 10.1161/CIRCGENETICS.111.961144 · DOI · Paper page
  34. Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5 · DOI · Paper page
  35. Farnier, 2014, PCSK9: From discovery to therapeutic applications, Archives of Cardiovascular Disease, 107, 58, 10.1016/j.acvd.2013.10.007 · DOI
  36. Garcia, 2001, Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein, Science, 292, 1934, 10.1126/science.1060458 · DOI · Paper page
  37. Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org
  38. Innerarity, 1987, Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding, Proceedings of the National Academy of Sciences, 84, 6919, 10.1073/pnas.84.19.6919 · DOI · Paper page
  39. Knowles, 2014, Reducing the burden of disease and death from familial hypercholesterolemia: a call to action, American Heart Journal, 168, 807, 10.1016/j.ahj.2014.09.001 · DOI
  40. Kreatsoulas, 2010, The impact of social determinants on cardiovascular disease, Canadian Journal of Cardiology, 26, 8C, 10.1016/S0828-282X(10)71075-8 · DOI · Paper page
  41. Krishnamurthi, 2013, Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010, Lancet Global Health, 1, e259, 10.1016/S2214-109X(13)70089-5 · DOI · Paper page
  42. Lefebvre, 2011. www.cochrane-handbook.org, Chapter 6: Searching for studies
  43. Lundh, 2017, Industry sponsorship and research outcome, Cochrane Database of Systematic Reviews, 10.1002/14651858.MR000033.pub3 · DOI · Paper page
  44. Lunven, 2014, A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects, Cardiovascascular Therapy, 32, 297, 10.1111/1755-5922.12093 · DOI
  45. Mancini, 2011, Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference, Canadian Journal of Cardiology, 27, 635, 10.1016/j.cjca.2011.05.007 · DOI · Paper page
  46. Marks, 2003, A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia, Atherosclerosis, 168, 1, 10.1016/S0021-9150(02)00330-1 · DOI · Paper page
  47. Moran, 2014, The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study, Circulation, 129, 1493, 10.1161/CIRCULATIONAHA.113.004046 · DOI · Paper page
  48. Navarese EP Kołodziejczak M Schulze V Gurbel PA Tantry U Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis Annals of Internal Medicine 2015 40 51 10.7326/M14-2957 · DOI · Paper page
  49. Newcombe, 2014, Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk, Evidence-Based Medicine, 19, 6, 10.1136/eb-2013-101340 · DOI
  50. Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosedand undertreated in the general population:guidance for clinicians to prevent coronary heart disease, European Heart Journal, 34, 3478, 10.1093/eurheartj/eht273 · DOI · Paper page
  51. Pfizer Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor (accessed 24 April 2017)
  52. Sabatine, 2015, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, New England Journal of Medicine, 372, 1500, 10.1056/NEJMoa1500858 · DOI · Paper page
  53. Schmidt, 2014, Comments on 'the use of propensity scores and observational data to estimate randomized controlled trial generalizability bias' by Taylor R. Pressler and Eloise E. Kaizar, Statistics in Medicine 2013, Statistics in Medicine, 33, 536, 10.1002/sim.5929 · doi:10.1002/sim.5929
  54. Schmidt, 2015, PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011748 · DOI
  55. Schmidt, 2016, Tailoring treatments using treatment effect modification, Pharmacoepidemiology and Drug Safety, 25, 355, 10.1002/pds.3965 · DOI
  56. Sudhof, 1985, The LDL receptor gene: a mosaic of exons shared with different proteins, Science, 228, 815, 10.1126/science.2988123 · DOI · Paper page
  57. Thompson, 1999, Explaining heterogeneity in meta-analysis: a comparison of methods, Statistics in Medicine, 18, 2693, 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V · doi:10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v
  58. Thompson, 2002, How should meta-regression analyses be undertaken and interpreted?, Statistics in Medicine, 21, 1559, 10.1002/sim.1187 · DOI · Paper page
  59. Willer, 2013, Discovery and refinement of loci associated with lipid levels, Nature Genetics, 45, 1274, 10.1038/ng.2797 · DOI

Cited by

See all 205

Metadata

Authors
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-04-28
Volume
10
Pages
CD011748-CD011748
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1898803325
Cited by
205
References
38
FWCI
20.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.